Why the study?
Do different chromogenic methods and instruments yield equivalent anti-Xa levels in patients on dalteparin or unfractionated heparin?
Do different chromogenic methods and instruments yield equivalent anti-Xa levels in patients on dalteparin or unfractionated heparin?
Different chromogenic anti-Xa assays and instruments produce clinically significant variations in anti-Xa levels, highlighting the need for method-specific therapeutic ranges.
No takes yet. Share an insight, caveat, or question.
Assay non-equivalence warrants caution in anti-Xa interpretation; leaves standardization and method-specific ranges open for further study.
Kovacs et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: